Profil
Frank J.
Hsu is a trustee at Karin Grunebaum Cancer Research Foundation.
He was a Senior Director-Medical at Genzyme Corp.
from 2002 to 2012, and Director-Immunology Research Programs at Yale Cancer Center from 1996 to 2002.
He was also a Researcher at Stanford University from 1990 to 1996.
From 2012 to 2013, he served as the Chief Medical Officer at Zyngenia, Inc. He was the Vice President & Head-Oncology at Immune Design Corp.
from 2014 to 2018.
Currently, he is the Chief Medical Officer at Oncternal Therapeutics, Inc. and the Chief Marketing Officer at Apexigen, Inc. Hsu received his undergraduate degree from Stanford University and his doctorate from Harvard Medical School.
Aktive Positionen von Frank Hsu
| Unternehmen | Position | Beginn |
|---|---|---|
Karin Grunebaum Cancer Research Foundation
Karin Grunebaum Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services The Karin Grunebaum Cancer Research Foundation funds cancer research focused on understanding causes, treatments, and cures, investing directly in promising researchers. The private company is based in Cambridge, MA. The foundation supports junior faculty and medical students primarily at Harvard Medical School and Boston University School of Medicine, offering fellowships, training programs, seminars, and an annual cancer research poster competition. It established the Karin Grunebaum Chair in Cancer Research at Boston University to promote interdisciplinary studies. The foundation supports research at institutions such as Dana-Farber Cancer Institute and Massachusetts General Hospital and encourages public support to further its mission. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Frank Hsu
| Unternehmen | Position | Ende |
|---|---|---|
| APEXIGEN, INC. | Technik-/Wissenschafts-/F&E-Leiter | 23.08.2023 |
| IMMUNE DESIGN CORP | Corporate Officer/Principal | 01.01.2018 |
Zyngenia, Inc.
Zyngenia, Inc. Drugstore ChainsRetail Trade Develops new class of biotherapeutics | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2013 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2012 |
Yale Cancer Center
Yale Cancer Center Hospital/Nursing ManagementHealth Services Provides treatment services for cancer patients | Corporate Officer/Principal | 01.01.2002 |
Ausbildung von Frank Hsu
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Zyngenia, Inc.
Zyngenia, Inc. Drugstore ChainsRetail Trade Develops new class of biotherapeutics | Retail Trade |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale Cancer Center
Yale Cancer Center Hospital/Nursing ManagementHealth Services Provides treatment services for cancer patients | Health Services |
Immune Design Corp.
Immune Design Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical and clinical-stage immunotherapy company | Health Technology |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karin Grunebaum Cancer Research Foundation
Karin Grunebaum Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services The Karin Grunebaum Cancer Research Foundation funds cancer research focused on understanding causes, treatments, and cures, investing directly in promising researchers. The private company is based in Cambridge, MA. The foundation supports junior faculty and medical students primarily at Harvard Medical School and Boston University School of Medicine, offering fellowships, training programs, seminars, and an annual cancer research poster competition. It established the Karin Grunebaum Chair in Cancer Research at Boston University to promote interdisciplinary studies. The foundation supports research at institutions such as Dana-Farber Cancer Institute and Massachusetts General Hospital and encourages public support to further its mission. | Commercial Services |
Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that manufactures pharmaceutical products | Health Technology |
Apexigen, Inc.
Apexigen, Inc. BiotechnologyHealth Technology Develops antibody therapeutics for the treatment of cancer | Health Technology |
















